$13.22 Million in Sales Expected for Kymera Therapeutics, Inc. (NASDAQ:KYMR) This Quarter

Wall Street analysts expect that Kymera Therapeutics, Inc. (NASDAQ:KYMRGet Rating) will post sales of $13.22 million for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Kymera Therapeutics’ earnings, with estimates ranging from $9.62 million to $17.50 million. Kymera Therapeutics reported sales of $18.52 million in the same quarter last year, which indicates a negative year over year growth rate of 28.6%. The business is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Kymera Therapeutics will report full-year sales of $79.40 million for the current year, with estimates ranging from $39.62 million to $113.49 million. For the next financial year, analysts anticipate that the business will report sales of $90.85 million, with estimates ranging from $40.00 million to $189.30 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Kymera Therapeutics.

Kymera Therapeutics (NASDAQ:KYMRGet Rating) last released its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.04). Kymera Therapeutics had a negative net margin of 194.23% and a negative return on equity of 30.40%. The company had revenue of $9.62 million during the quarter, compared to analyst estimates of $18.66 million. During the same period in the prior year, the business posted ($0.29) EPS. Kymera Therapeutics’s revenue was down 48.6% compared to the same quarter last year.

A number of brokerages have weighed in on KYMR. Wells Fargo & Company decreased their price objective on Kymera Therapeutics from $62.00 to $35.00 and set an “overweight” rating on the stock in a report on Wednesday. B. Riley decreased their price objective on Kymera Therapeutics from $67.00 to $50.00 in a report on Wednesday, May 4th. Credit Suisse Group initiated coverage on Kymera Therapeutics in a report on Thursday, April 28th. They issued an “outperform” rating and a $63.00 price objective on the stock. Morgan Stanley reduced their price target on Kymera Therapeutics from $68.00 to $66.00 and set an “equal weight” rating on the stock in a report on Wednesday, March 2nd. Finally, Zacks Investment Research lowered Kymera Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $61.75.

In related news, Director Bvf Partners L. P/Il acquired 10,100 shares of the stock in a transaction dated Friday, May 20th. The stock was acquired at an average cost of $14.00 per share, with a total value of $141,400.00. Following the completion of the transaction, the director now owns 2,036,860 shares in the company, valued at approximately $28,516,040. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Bvf Partners L. P/Il acquired 224,057 shares of the stock in a transaction dated Thursday, May 26th. The shares were bought at an average cost of $14.21 per share, with a total value of $3,183,849.97. Following the completion of the transaction, the director now owns 2,159,903 shares of the company’s stock, valued at approximately $30,692,221.63. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 384,157 shares of company stock valued at $6,265,250. Corporate insiders own 23.28% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Dark Forest Capital Management LP lifted its stake in Kymera Therapeutics by 3,292.0% during the third quarter. Dark Forest Capital Management LP now owns 848 shares of the company’s stock worth $50,000 after purchasing an additional 823 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Kymera Therapeutics by 57.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,227 shares of the company’s stock valued at $52,000 after buying an additional 447 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in Kymera Therapeutics in the fourth quarter valued at approximately $78,000. Point72 Hong Kong Ltd purchased a new stake in Kymera Therapeutics in the first quarter valued at approximately $53,000. Finally, Wells Fargo & Company MN lifted its stake in Kymera Therapeutics by 60.9% in the second quarter. Wells Fargo & Company MN now owns 1,430 shares of the company’s stock valued at $69,000 after buying an additional 541 shares during the last quarter. Hedge funds and other institutional investors own 77.73% of the company’s stock.

Kymera Therapeutics stock opened at $14.64 on Friday. The company’s fifty day moving average price is $27.71 and its 200 day moving average price is $40.73. Kymera Therapeutics has a 1 year low of $13.62 and a 1 year high of $69.12. The stock has a market capitalization of $757.24 million, a P/E ratio of -5.90 and a beta of 2.32.

Kymera Therapeutics Company Profile (Get Rating)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Read More

Get a free copy of the Zacks research report on Kymera Therapeutics (KYMR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kymera Therapeutics (NASDAQ:KYMR)

Want More Great Investing Ideas?

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.